Home

Stewards of critical care

Innoviva Specialty Therapeutics develops and delivers innovative therapies for patients in critical care and infectious disease

FOCUS

Addressing urgent needs

We are uniquely positioned to combat serious conditions and advance innovative treatment options in areas of high unmet need

Critical Care

Innovative solutions for patients with serious, life-threatening conditions

Infectious Diseases

Therapies for emerging illnesses caused by drug-resistant microorganisms

Global Mission

Advancing solutions for the most critical and urgent infections identified by the world's leading public health organizations

Our marketed products

Grounded in thorough research and a rigorous commitment to quality, our therapies include new, as well as established standards for critical care and infectious disease treatments.

Learn More

GIAPREZA®

(angiotensin II) 

XERAVA®

(eravacycline)

XACDURO®

(sulbactam for injection; durlobactam for injection)

Development pipeline

Product

Phase 1

Phase 2

Phase 3

ZOLIFLODACIN

Zoli is an investigational, first-in-class antibiotic for the treatment of uncomplicated gonorrhea infection in patients; positive Phase 3 data reported in November 2023

Company

An enduring influence

A growing and diversified biotechnology company, we are building a culture dedicated to delivering products that help save lives

Leadership

Led by a mission-driven team that blends rigorous medical science with the latest advances in pharmaceutical innovation

Learn More

Careers

Join a team where all colleagues can do their best work while making a lasting impact

Learn More